Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amaury Leruste

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
American Journal of Hematology|April 28, 2023
Molecular and clinicopathologic characterization of pediatric histiocytosesZofia Hélias-Rodzewicz, Jean Donadieu, Nathalie Terrones, et al.
Nature|May 15, 2024
Engineered CD47 protects T cells for enhanced antitumour immunitySean A Yamada-Hunter, Johanna Theruvath, Brianna J McIntosh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2026
Phase I/II study of the PARP inhibitor olaparib and irinotecan in children and young adults with recurrent/refractory malignancies: Arm D of the AcSé-ESMART trialSusanne A Gatz, Pablo Berlanga, Gwénaël Le Teuff, et al.
Blood|November 1, 2024
Childhood Langerhans cell histiocytosis hematological involvement: severity associated with BRAFV600E loadsJulian Thalhammer, Eric Jeziorski, Perrine Marec-Bérard, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
American Journal of Hematology|April 28, 2023
Molecular and clinicopathologic characterization of pediatric histiocytosesZofia Hélias-Rodzewicz, Jean Donadieu, Nathalie Terrones, et al.
Nature|May 15, 2024
Engineered CD47 protects T cells for enhanced antitumour immunitySean A Yamada-Hunter, Johanna Theruvath, Brianna J McIntosh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2026
Phase I/II study of the PARP inhibitor olaparib and irinotecan in children and young adults with recurrent/refractory malignancies: Arm D of the AcSé-ESMART trialSusanne A Gatz, Pablo Berlanga, Gwénaël Le Teuff, et al.
Blood|November 1, 2024
Childhood Langerhans cell histiocytosis hematological involvement: severity associated with BRAFV600E loadsJulian Thalhammer, Eric Jeziorski, Perrine Marec-Bérard, et al.
Pageof 3